Urol. praxi. 2021;22(2):65-69 | DOI: 10.36290/uro.2021.006
Conservative therapy of non-neurogenic lower urinary tract dysfunctions
- Urologické oddělení ÚVN, Praha
- Urologická klinika FNKV a 3. LF UK, Praha
Possibilities of pharmacological and non-pharmacological therapy of lower urinary tract dysfunctions according to individual types are presented. Overactive bladder is well controlled by non-pharmacological therapy, especially electrostimulation methods, yet antimuscarinic therapy dominates. In conservative therapy of benign prostatic hyperplasia, pharmacotherapy dominates with the increasing importance of the combination of alpha-blockers and 5-alpha reductase inhibitors in particular. Intermittent catheterization is effective therapy of detrusor underactivity. Conservative therapy of stress incontinence is based on reduction of obesity and pelvic floor muscle training. In case of non-pharmacological and pharmacological therapy failure, symptomatic and supportive therapy is recommended, such as the use of incontinence aids. This could be the last way to improve the quality of life despite the insufficient effect of conservative therapy of these disorders.
Keywords: lower urinary tract dysfunction, overactive bladder, detrusor underactivity, benign prostatic hyperplasia, stress urinary incontinence.
Accepted: February 1, 2021; Prepublished online: February 1, 2021; Published: June 2, 2021 Show citation
References
- Zachoval R, Záleský M, Lukes M, Mareš J, Urban M, Palascak P. Funkce dolních močových cest a jejich poruchy. Čes Fyziol. 2000; 49: 134-44.
- Záleský M, Zachoval R. Epidemiologie a socioekonomické dopady hyperaktivity močového měchýře. Prakt Lék 2009; 89(6): 312-316.
- Irwin DE, Milsom I, Kopp Z, et al. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol 2009; 56(1): 14-20.
Go to original source... 
Go to PubMed... - Krhut J, Zachoval R, Havránek O, Němec D, Holý P. Nykturie - racionální diagnostika a terapie. Urol. praxi 2011; 12(6): 345-348.
- Nambiar AK, Bosch R, Cruz F, et al. EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. European Urology 2018; 73(4): 596-609. Go to original source... Go to PubMed...
- Bryant CM, Dowell CJ, Fairbrother G. Caffeine reduction education to improve urinary symptoms. Br J Nurs 2002; 11(8): 560-5. Go to original source... Go to PubMed...
- Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev 2012(12): CD003193. Go to original source...
- Berghmans B, Hendriks E, Bernards A, de Bie R, Omar MI. Electrical stimulation with non-implanted electrodes for urinary incontinence in men. Cochrane Database Syst Rev 2013; (6): CD001202. Go to original source...
- Kalder M, Pantazis K, Dinas K, et al. Discontinuation of treatment using anticholinergic medications in patients with urinary incontinence. Obstet Gynecol 2014; 124(4): 794-800. Go to original source... Go to PubMed...
- Trachta J, Wachter J, Kriz J. Chronic Urinary Retention due to Fowler's Syndrome. European J Pediatr Surg Rep 2018; 6(1): e77-80. Go to original source... Go to PubMed...
- Kaplan SA. Current role of α-blockers in the treatment of benign prostatic hyperplasia. BJU International 2008; 102: 3-7. Go to original source... Go to PubMed...
- Schwinn DA, Michelotti GA. α1-Adrenergic receptors in the lower urinary tract and vascular bed: potential role for the α1d subtype in filling symptoms and effects of ageing on vascular expression. BJU International 2000; 85(s2): 6-11. Go to original source... Go to PubMed...
- Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology 2009; 74(6): 1318-22. Go to original source... Go to PubMed...
- Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36(1): 1-13. Go to original source... Go to PubMed...
- Gravas S, Oelke M. Current status of 5α-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol 2010; 28(1): 9-15. Go to original source... Go to PubMed...
- McConnell JD, Lieber M, Nickel JC. The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia. N Engl J Med 1998; 338(9): 557-563. Go to original source... Go to PubMed...
- McConnell JD, Roehrborn CG, Bautista OM, et al. The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. N Engl J Med 2003; 349(25): 2387-98. Go to original source... Go to PubMed...
- Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57(1): 123-31. Go to original source... Go to PubMed...
- Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012; 61(5): 994-1003. Go to original source... Go to PubMed...
- Casabé A, Roehrborn CG, Da Pozzo LF, et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol 2014; 191(3): 727-33. Go to original source... Go to PubMed...
- Záleský M, Zachoval R, Urban M. Duloxetin v terapii inkontinence. Farmakoterapie 2005; 1(5): 410-2.